BCOR
BCOR (BCL-6 corepressor) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.
Overview
Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor.
CIViC holds 13 clinical evidence items and 4 assertions across 2 variants. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes literature 0.95, affected pathway 0.61, genetic association 0.52, somatic mutation 0.91). IntOGen calls it a driver in 23 cohorts (5 activating, 18 loss-of-function), covering Adrenocortical Carcinoma, Acute Myeloid Leukaemia, Cholangiocarcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Colorectal Adenocarcinoma, Glioblastoma Multiforme and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BCOR (BCL-6 corepressor) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.
- 1 · What it is
BCOR (BCL-6 corepressor) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.
- 2 · What goes wrong in cancer
Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3.
- 3 · How drugs use it
No product in this corpus aims at BCOR yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:20893 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6W2J9 (protein name, function text, keywords and locations (REST API)); CIViC gene BCOR (13 evidence items, 4 assertions, 2 variants; diseases: Kidney Clear Cell Sarcoma, Central Nervous System Tumour With BCOR Internal Tandem Duplication, Sarcoma, Stomach Cancer, Myelodysplastic Syndrome (GraphQL API, CC0)); Open Targets ENSG00000183337 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: colorectal cancer 0.59, gastric cancer 0.51, endometrial cancer 0.62, melanoma 0.55, acute myeloid leukaemia 0.54, acute lymphoblastic leukaemia 0.61 (GraphQL API, CC0)); IntOGen BCOR (driver in 23 cohorts (Act 5, LoF 18); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2). Location: Nucleus (UniProt). Locus Xp11.4 (HGNC).
- Leukaemia: Open Targets association 0.69 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.63 with non-Hodgkin lymphoma (MONDO_0018908)
- Endometrial cancer: Open Targets association 0.62 with endometrial cancer (MONDO_0011962); IntOGen driver in 3 cohorts (UCEC)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056); CIViC evidence names this disease
- Sarcomas: CIViC evidence names this disease
- Myelodysplastic syndromes / neoplasms: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 18 cohorts; CIViC holds 13 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Kidney Clear Cell Sarcoma; Central Nervous System Tumour With BCOR Internal Tandem Duplication; Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"BCOR" OR ABSTRACT:"BCOR" OR TITLE:"BCL6 corepressor" OR ABSTRACT:"BCL6 corepressor" OR TITLE:"BCL-6 corepressor" OR ABSTRACT:"BCL-6 corepressor" OR TITLE:"FLJ20285" OR ABSTRACT:"FLJ20285" OR TITLE:"KIAA1575" OR ABSTRACT:"KIAA1575") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCOR, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSH2B3
Shares Myelodysplastic syndromes / neoplasms (MDS), Leukaemia (all types), Endometrial cancer, Non-Hodgkin lymphoma (all types).
- TargetPIK3R1
Shares Leukaemia (all types), Endometrial cancer, Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetCTCF
Shares Leukaemia (all types), Endometrial cancer, Non-Hodgkin lymphoma (all types), CIViC.
- TargetETV6
Shares Myelodysplastic syndromes / neoplasms (MDS), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetFBXW7
Shares Leukaemia (all types), Endometrial cancer, Non-Hodgkin lymphoma (all types), CIViC.
- TargetPLCG1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetU2AF1
Shares Myelodysplastic syndromes / neoplasms (MDS), Leukaemia (all types), Endometrial cancer, CIViC.
- TargetASXL1
Shares Myelodysplastic syndromes / neoplasms (MDS), Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC.